HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Abstract : Background: Targeted lung denervation (TLD) is a novel bronchoscopic therapy that disrupts parasympathetic pulmonary nerve input to the lung reducing clinical consequences of cholinergic hyperactivity. The AIRFLOW-1 study assessed safety and TLD dose in patients with moderate-to-severe, symptomatic COPD. This analysis evaluated the long-term impact of TLD on COPD exacerbations, pulmonary function, and quality of life over 3 years of follow up. Methods: TLD was performed in a prospective, energy-level randomized (29 W vs 32 W power), multicenter study (NCT02058459). Additional patients were enrolled in an open label confirmation phase to confirm improved gastrointestinal safety after procedural modifications. Durability of TLD was evaluated at 1, 2, and 3 years post-treatment and assessed through analysis of COPD exacerbations, pulmonary lung function, and quality of life. Results: Three-year follow-up data were available for 73.9% of patients (n = 34). The annualized rate of moderate to severe COPD exacerbations remained stable over the duration of the study. Lung function (FEV 1 , FVC, RV, and TLC) and quality of life (SGRQ-C and CAT) remained stable over 3 years of follow-up. No new gastrointestinal adverse events and no unexpected serious adverse events were observed. Conclusion: TLD in COPD patients demonstrated a positive safety profile out to 3 years, with no late-onset serious adverse events related to denervation therapy. Clinical stability in lung function, quality of life, and exacerbations were observed in TLD treated patients over 3 years of follow up.
Complete list of metadata

https://hal.univ-reims.fr/hal-03170571
Contributor : Valerian Dormoy Connect in order to contact the contributor
Submitted on : Tuesday, March 16, 2021 - 12:00:53 PM
Last modification on : Friday, April 1, 2022 - 3:56:37 AM
Long-term archiving on: : Thursday, June 17, 2021 - 7:25:14 PM

File

ChristophePison_RespirRes_2021...
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Christophe Pison, Pallav L. Shah, Dirk-Jan Slebos, Vincent Ninane, Wim Janssens, et al.. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes. Respiratory Research, BioMed Central, 2021, 22, pp.62. ⟨10.1186/s12931-021-01664-5⟩. ⟨hal-03170571⟩

Share

Metrics

Record views

81

Files downloads

44